Business Wire

FONDATION-IPSEN

26.11.2015 15:01:22 CET | Business Wire | Press release

Share
The 2015 Fondation IPSEN Longevity Prize Has Been Awarded to Steven N. Austad

The 20th annual Longevity Prize of the Fondation IPSEN has been awarded to Steven N. Austad (University of Alabama at Birmingham, USA ), in recognition of his outstanding leadership in the domain of the comparative biology of aging (especially the study of species resisting to aging), by an international jury led by Thomas Kirkwood (Newcastle University, Newcastle, UK ). He received the €20,000 prize on November 21st , 2015 at the Gerontology Society of America (GSA) in Orlando, USA where he presented an outstanding lecture.

“Evolution is smarter than you are.” That quote from biochemist Leslie Orgel forms the basis for looking to nature for creative ways to slow the damaging processes of aging. Ironically, the laboratory animals scientists generally use to try to understand aging processes – and learn how to retard them – are demonstrably unsuccessful at combating these degenerative processes. It doesn’t take long to determine whether the researchers have succeeded in lengthening their health- and lifespan. On the other hand, methods for making an animal that normally lives 2 years survive to age 4, may not be relevant for an animal – humans – that already lives 80 years or more. A complementary approach is to scour nature for animals that nature has already given the tools to combat aging successfully and to try to discover what those tools are and how they work. Animals that are more successful than humans at resisting aging processes are abundant on earth. The research of Steven N. Austad has employed a number of such species over the years.

Dr. Austad is Distinguished Professor and Chair of the Department of Biology at the University of Alabama at Birmingham and also Scientific Director of the American Federation for Aging Research. After receiving his PhD degree from Purdue University, he accepted his first faculty position as Assistant Professor at Harvard University in 1986. He subsequently moved to the University of Idaho where he became full professor in 1997. In 2004, he joined the Barshop Institute for Longevity & Aging Studies at the University of Texas Health Science Center San Antonio in San Antonio, Texas before moving to his current position in 2014. His research encompasses many aspects of the biology of aging from the molecular to the population level. His research specialty is the identification and study of nontraditional species – particularly exceptionally long-lived species – for insight into processes of slow aging. Dr. Austad’s research has won multiple previous awards, including the Geron Corporation-Samuel Goldstein Distinguished Publication Award, the Nathan A. Shock Award, the Robert W. Kleemeier Award, the Purdue Outstanding Alumnus Award, and the Irving S. Wright Award of Distinction.

Previous laureates of the Longevity Prize
Founded in 1996, the Longevity Prize of the Fondation IPSEN has been awarded to renowned specialists: Caleb E. Finch (Los Angeles, 1996) , Vaino Kannisto (Lisboa, 1997), Roy L. Walford (Los Angeles, 1998), John Morley (St Louis,1999), Paul & Margret Baltes (Berlin, 2000), Justin Congdon (Aiken, 2001), George Martin (Seattle, 2002), James Vaupel (Rostock, 2003), Linda Partridge (London, 2004), Sir Michael Marmot (London, 2005), Cynthia Kenyon (San Francisco, 2006), David Barker (Southampton, 2007), Gerald McLearn (University Park, 2008 ), Jacques Vallin (Paris, 2009), Judith Campisi (Novato, 2010), Tom Kirkwood (Newcastle, 2011), Linda Fried (New York, 2012), Gary Ruvkun (Boston, 2013), Luigi Ferrucci (Baltimore, 2014).

The jury members of the Longevity Prize
Thomas Kirkwood (Newcastle University, Newcastle, UK ), President
Judith Campisi (Buck Institute for Research on Ageing, Novato, USA ), Eileen Crimmins (University of Southern California, Los Angeles, USA ), Caleb Finch (University of Southern California, Los Angeles, USA ), Bernard Jeune (Odense Universitet, Odense, Denmark ), George Martin (University of Washington, Seattle, USA ), Jean-Marie Robine (INSERM, Démographie et Santé, Montpellier, France ), Bruno Vellas (Hôpital Purpan, Toulouse, France ) and a Fondation IPSEN representative.

About the Fondation IPSEN
Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge. The long-standing action of the Fondation IPSEN aims at fostering the interaction between researchers and clinical practitioners, which is essential due to the extreme specialization of these professions. The ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche , dedicated to six main themes: Alzheimer's disease, neurosciences, longevity, endocrinology, the vascular system and cancer science. Moreover the Fondation IPSEN has started since 2007 several meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the Days of Molecular Medicine Global Foundation as well as with the science journals Nature , Cell and Science . The Fondation IPSEN produced several hundred publications; more than 250 scientists and biomedical researchers have been awarded prizes and research grants.
www.fondation-ipsen.org

Contact:

Image Sept
Isabelle de Segonzac, Tel: +33 (0)1 53 70 74 70
Email: isegonzac@image7.fr

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release

Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru

eM Client 11 Launches: A European Outlook Alternative Bringing AI Freedom, Digital Sovereignty, and Next-Generation Productivity14.10.2026 18:16:00 CEST | Press release

eM Client, the European developer of the popular email and productivity application used by millions worldwide, today announced the release of eM Client 11, its most significant update yet. The new version introduces advanced AI capabilities, and major productivity improvements, strengthening its position as an independent alternative to Microsoft Outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014945464/en/ eM Client 11 main window AI Without Vendor Lock-In eM Client 11 introduces a powerful AI Assistant that enables users to search, summarize, organize, and manage emails using natural language. Additional features include personalized AI writing, context-aware quick replies, automatic task and event detection, and AI-powered email rules. Unlike traditional AI integrations, eM Client 11 supports Bring Your Own Key (BYOK), allowing organizations to connect compatible AI providers and models of their choice. The re

iQmetrix and Stratus HR Partner to Give Wireless Retailers a Complete, Outsourced HR Department14.10.2026 17:15:00 CEST | Press release

New integration connects the employee lifecycle to the store – new hires, terminations, rehires, position moves, and security-role updates flow straight into the POS, with payroll, benefits, and compliance handled by Stratus HR’s certified experts. Stratus HR, a full-service human resources outsourcing provider, today announced a partnership with iQmetrix, the Intelligent Commerce Operating System for telecom. As a Professional Employer Organization (PEO), Stratus HR becomes the complete, outsourced HR partner for wireless retailers on iQmetrix – payroll, benefits, compliance, and on-call HR experts – so retail teams stay focused on selling and serving customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014178512/en/ Fully integrated with iQmetrix, Stratus HR’s custom-built technology connects the employee lifecycle to the store: new hires, terminations, rehires, position moves, and security-role updates flow straig

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye